All In Biotech

Drug Trial Radar · NCT06693895

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

A Phase 3a, Observer-blind, Randomized, Controlled Study to Evaluate the Safety of an Investigational Varicella Vaccine Compared With Varivax, Administered as a First Dose to Healthy Children 12 to 15 Months of Age

Last checked: Nov 20, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

750

Planned (sponsor's estimate)

Start

Nov 26, 2024

Primary completion

Nov 23, 2026

Study completion Nov 23, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 15 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess how well-tolerated GSK's investigational varicella vaccine (VNS Vaccine) is, in comparison to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted on healthy children aged 12 to 15 months, and who have neither contracted varicella nor received a varicella vaccination.

Conditions

  • Chickenpox

Interventions

  • Investigational varicella vaccineBiological

    1 dose of investigational varicella vaccine administered subcutaneously.

  • Marketed varicella vaccineBiological

    1 dose of marketed varicella vaccine administered subcutaneously.

  • Measles, mumps, and rubella vaccineBiological

    1 dose of measles, mumps, and rubella vaccine co-administered subcutaneously or intramuscularly.

  • Hepatitis A vaccineBiological

    1 dose of hepatitis A vaccine co-administered intramuscularly.

  • PCV (pneumococcal conjugate vaccine) 13Biological

    1 dose of 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.

  • PCV 20Biological

    1 dose of 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.

  • VaxneuvanceBiological

    1 dose of 15-valent pneumococcal conjugate (Vaxneuvance) vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants reporting each solicited administration site eventsTime frame: Day 1 (post-dose) to Day 4
  2. Percentage of participants reporting each solicited systemic eventTime frame: Day 1 (post-dose) to Day 15
  3. Percentage of participants reporting each solicited systemic event in terms of feverTime frame: Day 1 (post-dose) to Day 22
  4. Percentage of participants reporting each solicited administration site eventsTime frame: Day 1 (post-dose) to Day 43
  5. Percentage of participants reporting solicited systemic eventsTime frame: Day 1 (post-dose) to Day 43
  6. Percentage of participants reporting unsolicited adverse events (AEs)Time frame: Day 1 (post-dose) to Day 43
  7. Percentage of participants reporting medically attended AEs (MAAE)Time frame: Day 1 (post-dose) to Day 181 (study end)
  8. Percentage of participants reporting serious adverse events (SAEs)Time frame: Day 1 (post-dose) to Day 181 (study end)

Locations

46 sites in 8 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Phoenix, Arizona · Withdrawn

  • GSK Investigational Site

    Tucson, Arizona · Withdrawn

  • GSK Investigational Site

    Huntington Park, California · Recruiting

  • GSK Investigational Site

    National City, California · Recruiting

  • GSK Investigational Site

    West Covina, California · Recruiting

  • GSK Investigational Site

    Hialeah, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Chicago, Illinois · Recruiting

  • GSK Investigational Site

    El Dorado, Kansas · Withdrawn

  • GSK Investigational Site

    Lafayette, Louisiana · Recruiting

  • GSK Investigational Site

    Mankato, Minnesota · Recruiting

  • GSK Investigational Site

    Lincoln, Nebraska · Recruiting

  • GSK Investigational Site

    Cincinnati, Ohio · Recruiting

  • GSK Investigational Site

    Dallas, Texas · Recruiting

  • GSK Investigational Site

    Dallas, Texas · Withdrawn

  • GSK Investigational Site

    Houston, Texas · Recruiting

  • GSK Investigational Site

    Richmond, Texas · Recruiting

  • GSK Investigational Site

    Richmond, Texas · Recruiting

  • GSK Investigational Site

    San Antonio, Texas · Withdrawn

  • GSK Investigational Site

    Roy, Utah · Completed

  • GSK Investigational Site

    Syracuse, Utah · Recruiting

  • GSK Investigational Site

    Richmond, Virginia · Recruiting

  • GSK Investigational Site

    Vienna, Virginia · Withdrawn

  • GSK Investigational Site

    Burgas, Bulgaria · Withdrawn

  • GSK Investigational Site

    Gabrovo, Bulgaria · Recruiting

  • GSK Investigational Site

    Kyustendil, Bulgaria · Recruiting

  • GSK Investigational Site

    Plovdiv, Bulgaria · Recruiting

  • GSK Investigational Site

    Rousse, Bulgaria · Recruiting

  • GSK Investigational Site

    Sevlievo, Bulgaria · Recruiting

  • GSK Investigational Site

    Yambol, Bulgaria · Withdrawn

  • GSK Investigational Site

    Aarhus N, Denmark · Recruiting

  • GSK Investigational Site

    Copenhagen, Denmark · Recruiting

  • GSK Investigational Site

    Hvidovre, Denmark · Recruiting

  • GSK Investigational Site

    Odense C, Denmark · Recruiting

  • GSK Investigational Site

    Tallinn, Estonia · Recruiting

  • GSK Investigational Site

    Tallinn, Estonia · Recruiting

  • GSK Investigational Site

    Hong Kong, Hong Kong · Recruiting

  • GSK Investigational Site

    Shatin, Hong Kong · Recruiting

  • GSK Investigational Site

    Kaunas, Lithuania · Recruiting

  • GSK Investigational Site

    Kaunas, Lithuania · Recruiting

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.